Biosynth, a global provider of essential raw materials and services to the life sciences industry, announced that its Board of Directors has appointed Matt Gunnison as its new Chief Executive Officer and member of the Board of Directors, effective immediately. In addition, the Board has simultaneously appointed Kieran Murphy as Chairman.
Matt Gunnison succeeds Urs Spitz, under whose leadership Biosynth achieved impressive growth and consolidated its position in the life sciences sector. Urs Spitz will continue to serve on the Board of Directors.
” We are grateful to Urs for his important contribution to developing Biosynth into the innovative and prosperous company it is today. We warmly welcome Matt as the new CEO. His vision and many years of experience will be central to the company’s next chapter,” explains Kugan Sathiyanandarajah, Partner at KKR and Head of Europe for the implementation of KKR’s Health Care Strategic Growth strategy in the healthcare sector.
” I am delighted to be joining Biosynth at this exciting time. Under Urs’ leadership, the company has built a robust foundation and I look forward to working with the talented team to further accelerate our growth and innovation cycles. We will continue to provide critical raw materials and services that advance the life sciences and make a tangible contribution to global health,” said Matt Gunnison.
Also Read: Transgene & ProBioGen Partner for Cancer Vaccine Innovation
” It is a great honor to be appointed Chairman of Biosynth and I look forward to working with Matt and the entire team to continue to lead the company on its growth path. Biosynth is a key innovator in the life sciences industry and I am confident that we have the leadership and vision to continue to be successful,” commented Kieran Murphy.
” I am very proud of what Biosynth has achieved so far. I would like to congratulate Matt and Kieran on their new roles and wish them and the entire Biosynth team every success in the years to come. In my role as a member of the Board of Directors, I will continue to support them as they lead Biosynth into this new phase,” explains Urs Spitz.
Matt currently serves as CEO of Gamma Biosciences, a life sciences investment platform he co-founded with leading global investment firm KKR. He brings nearly two decades of experience in the healthcare and life sciences industry. At Gamma, Matt oversaw the acquisition and management of a portfolio of growth companies in the biopharmaceutical industry. Prior to joining Gamma, he held various roles at GE Healthcare – most recently as Head of Corporate Development for the $19 billion business unit of General Electric Co. Matt holds a BA in economics from Georgetown University and a JD from the University of Michigan.
Kieran previously served as a Senior Advisor at KKR and will join Biosynth from Gamma Biosciences, where he has served as Chairman since 2022. He brings decades of management and board experience in the healthcare and life sciences industry, including as former President and CEO of GE Healthcare and GE Healthcare Life Sciences.
SOURCE: Businesswire